You are here

Article Text

Article menu
Download PDFPDF
Letter
Authors’ response
  1. M R Kraus,
  2. A Schäfer,
  3. M Scheurlen
  1. Medizinische Klinik und Poliklinik II, Department of Gastroenterology and Hepatology, University of Würzburg, Würzburg, Germany
  1. Dr M R Kraus, Medizinische Klinik und Poliklinik II, University of Würzburg, Klinikstr. 6–8, D-97070 Würzburg, Germany; kraus_m{at}klinik.uni-wuerzburg.de

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In their letter, Robaeys et al refer to our study1 on the antidepressant treatment of interferon (IFN)-induced depression in patients with chronic hepatitis C virus (HCV) infection.

    We fully agree with the authors’ statements that (1) prescription of a selective serotonin reuptake inhibitor (SSRI) is indicated and highly effective1 when clinically relevant symptoms of depression emerge and (2) the exact mechanisms by which SSRIs reduce depression in these patients are still unclear. Nevertheless, with respect to the latter point, …

    View Full Text

    Linked Articles